SCHEMBL4904517

SCHEMBL4904517

C[C@H]1CCN(C(=O)c2ccc(-c3ccc4[nH]ccc4c3)c(C(=O)CCCCN(C)C)c2)c2ccccc2N1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OXTR P30559 2/20 0.37
ACHE P22303 2/20 0.36
HTR4 Q13639 2/20 0.36
CTNNB1 P35222 4/20 0.35
WNT3A P56704 4/20 0.35
MAPK14 Q16539 2/20 0.34
SIGMAR1 Q99720 1/20 0.34
PDK1 Q15118 1/20 0.34
PDK2 Q15119 1/20 0.34
PDK3 Q15120 1/20 0.34
PDK4 Q16654 1/20 0.34
ACACB O00763 1/20 0.34
ACACA Q13085 1/20 0.34
AVPR2 P30518 1/20 0.33
FASN P49327 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.33
GHSR Q92847 1/20 0.33
DRD2 P14416 1/20 0.32
DRD3 P35462 1/20 0.32
MELK Q14680 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4910140 0.92 ACHE (0.37) OXTRACHEHTR4CTNNB1WNT3A
SCHEMBL14432421 0.90 ACHE (0.36) OXTRACHEHTR4CTNNB1WNT3A
SCHEMBL4908666 0.90 OXTR (0.35) OXTRMAPK14PDK1PDK2PDK3
SCHEMBL14258848 0.89 OXTR (0.36) OXTRMAPK14PDK1PDK2PDK3
SCHEMBL4904291 0.88 ACHE (0.34) OXTRACHEHTR4CTNNB1WNT3A
SCHEMBL4912067 0.88 MAPK14 (0.37) OXTRACHEHTR4CTNNB1WNT3A
SCHEMBL14258886 0.87 KDR (0.39) OXTRMAPK14ACACBACACAFASN
SCHEMBL4910984 0.87 PDK1 (0.38) OXTRMAPK14PDK1PDK2PDK3
SCHEMBL4902070 0.87 PDK1 (0.38) OXTRMAPK14PDK1PDK2PDK3
SCHEMBL5242825 0.86 OXTR (0.40) OXTRMAPK14ACACBACACAFASN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080076760-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION WAKAMOTO PHARMACEUTICAL CO., LTD (JP) 2008-03-27 US disclosed
US-20080076760-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION WAKAMOTO PHARMACEUTICAL CO., LTD (JP) 2008-03-27 US disclosed
US-20080076760-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION WAKAMOTO PHARMACEUTICAL CO., LTD (JP) 2008-03-27 US disclosed
EP-1820799-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION Wakamoto Pharmaceutical Co., Ltd. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076760-A1 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION GABRA5, GABRA1, GABRB1 OXTR 908/4885ACHE 4657/4885HTR4 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.